NEW ANGIOTENSIN II RECEPTOR BLOCKER FIMASARTAN IN MILD-TO-MODERATE HYPERTENSION: POST-HOC ANALYSIS OF RESULTS OF REGISTRATION TRIAL IN RUSSIA